Burjeel Holdings Plc · ADX:BURJEEL
Burjeel — Q1 2025 Earnings Presentation
18 slides from Burjeel's earnings presentation, May 2025
Slide 1: Q1 2025 Results
May 2025 Q12025 Results Leading Super-Specialty Healthcare Provider in MENA
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burjeel Holdings PLC None of the Company or its subsidiaries or any of their affiliates or based on publicly available information and non-public advisors make any representation or warranty as to the fairness, information to assist you in making a p
Slide 3: Key Highlights
Key Highlights Leading Super-Specialty Healthcare Provider in MENA
Slide 4: Q1'25 Results: Key Learnings & Strategic Responses
Q1’25 Results: Key Learnings & Strategic Responses Q1’25 Financial Areas of Pressure Root Causes & Context Strategic Response Results Patient Footfall Drop in • Ramadan impact was • Refine planning assumptions and scale underestimated and more appointment capacity in Q2 to capture March Revenue pron
Slide 5: Recent Business Developments
Recent Business Developments Expanding UAE’s Specialized Oncology Care Burjeel Cancer Institute expanded with a new Cancer Care Center in Al Ain and a dedicated Breast Cancer Clinic at BMC, offering comprehensive oncology services, advanced diagnostics, and personalized treatments. Building Leading
Slide 6: Recent Medical Developments
Recent Medical Developments Partnered with US-based Caring Cross to locally manufacture CAR-T cell therapies, which enable a patient’s immune cells to attack cancer cells, at a 90% lower cost compared to current markets, making the treatment more accessible and affordable in the MENA region. Reached
Slide 7: Performance Review
Performance Review Leading Super-Specialty Healthcare Provider in MENA
Slide 8: Q1'25 Group Patient Footfall Trends
Q1’25 Group Patient Footfall Trends Group Inpatient Footfall, k Group Outpatient Footfall, k +11.4% • Jan–Feb’25 accounted for 86% of the +5.2% • Outpatient footfall in Jan–Feb’25 rose 7.9% incremental growth in Q1 inpatient footfall, YoY, driven by the continued ramp-up of key 43 driven by the ramp
Slide 9: Revenue & EBITDA Analysis Across Key Business Segments
Revenue & EBITDA Analysis Across Key Business Segments Group Revenue, AED m Segment-Wise Revenue & EBITDA, AED m • Top-line growth in Jan–Feb’25 rose 14.5% YoY, +101 1,375 • Hospital revenue grew 3.6% +5.7% supported by strong patient footfall growth YoY to AED 1,126 million. (+8.0% YoY), healthy su
Slide 10: Burjeel Medical City Performance
Burjeel Medical City Performance Total Patients, k Revenue, AED m1 EBITDA, AED m1 +14.7% +11.2% 141 +20.4% +17.8% 315 123 +20.3% 283 100 226 53 83 192 44 Jan - Feb'24 Jan - Feb'25 Q1'24 Q1'25 Jan - Feb'24 Jan - Feb'25 Q1'24 Q1'25 Q1'24 Q1'25 • Burjeel Medical City (BMC) delivered robust revenue grow
Slide 11: Operating Cost Trends & EBITDA Variance Analysis
Operating Cost Trends & EBITDA Variance Analysis Group OPEX Breakdown,1 AED and % of Revenue Group EBITDA Analysis,2 AED m 1,102 1,098 84.4% 86.2% 963 79.9% +69 (58) 168 157 +101 (22) 111 28 39 12.8% 12.3% +1 261 9.2% 2.2% 3.0% 234 (16) 22 1.8% (15) (45) 328 316 24.8% 302 25.0% 25.2% +12 181 (22.9%)
Slide 12: Cash Flow & Profitability Performance
Cash Flow & Profitability Performance Cash Flow from Operating Activities, AED m Group Net Profit Analysis, AED m 566 +69 (135) 500 358 104 328 142 +12 (9) 115 (8) +6 39 2021 2022 2023 2024 Q1’24 Q1’25 Q1’24 Q1'24 Revenue Revenue OPEX OPEX Change Change… D&A Finance D&A Finance costs Taxes Taxes Q1’
Slide 13: Capital Structure & Leverage Overview
Capital Structure & Leverage Overview AED m FY 2023 FY 2024 Q1’25 Debt Maturity as of 31 March 2025 Bank balances and cash 170 238 270 Interest-bearing loans and borrowings 1,164 1,208 1,341 243 237 204 214 Bank overdrafts – -- -- 201 Bank debt1 1,164 1,208 1,341 131 Net debt 994 970 1,071 110 Lease
Slide 14: Guidance
Guidance Leading Super-Specialty Healthcare Provider in MENA
Slide 15: FY2025 Guidance Under Review, Mid-Term Confidence Intact
FY2025 Guidance Under Review, Mid-Term Confidence Intact FY 2025 (Expected) Mid-term (2026-2028) • UAE: 1 advanced care oncology center (Dubai), 1 • UAE: 1 hospital (Dubai), 1 day surgery center (Ras Al-Khaimah), 3 Expansion fertility clinic (Al Ain), 6 medical center medical center • KSA: 31 Physio
Slide 16: Q&A Appendix
Q&A Appendix Leading Super-Specialty Healthcare Provider in MENA
Slide 17: Group & Segment Summary
Group & Segment Summary Group financial summary Segmental financial summary AED millions Q1’25 Q1’24 AED millions Q1’25 Q1’24 Revenue 1,274 1,205 Revenue 1,274 1,205 Inventories consumed (316) (302) Hospitals1 1,126 1,087 Medical Centers1 108 92 Doctors’ and other employees’ salaries (586) (528) Pha
Slide 18: IR Contacts
IR Contacts May 2025 Sergei Levitskii Director of Investor Relations sergei.levitskii@burjeelholdings.com T: +971 2 3041 111 ir@burjeelholdings.com F: +971 2 2222 363 M: +971 503802383 PO Box 7400, Abu Dhabi, UAE Investor Calendar Company Website